Contact this trialFirst, we need to learn more about you.
Enzyme Replacement Therapy
Venglustat + Cerezyme for Gaucher Disease
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is evaluating a new drug, venglustat, for the treatment of Gaucher Disease Type 3. The trial is divided into four parts. The first part is to screen patients and evaluate their biomarkers. The second and third parts are to study the safety and efficacy of venglustat in combination with another drug, Cerezyme. The fourth part is to study the safety and efficacy of venglustat as a monotherapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.